All In Biotech

Drug Trial Radar · NCT06866548

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

7

Planned (sponsor's estimate)

Start

Mar 10, 2025

Primary completion

Nov 11, 2025

Study completion Nov 2028

Sponsor

Lead sponsor
Shanghai Changzheng HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is designed to evaluate the safety and efficacy of anti-IGF-1R mAb in combination with anti-PD-1 mAb in patients with mCRPC.

Conditions

  • mCRPC

Interventions

  • anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)Drug

    Drug: Teprotumumab/IBI311 Given by IV infusion Initiate dosing with 10 mg/kg for first infusion, followed by 20 mg/kg every 3 weeks. Drug: Tislelizumab Given by IV infusion 200 mg every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and adverse event incidence rateTime frame: Through primary completion of study which may take up to 6 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Changzheng Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.